RARE News

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Pomerantz LLP Highlights Class Action Filing Against Ultragenyx Pharmaceutical Inc. – RARE

Ultragenyx to Participate at Investor Conferences in March

ROSEN, A RANKED AND LEADING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

LEVI & KORSINSKY, LLP: PHASE III CLINICAL TRIAL DESIGN AND ENDPOINT SELECTION AT CENTER OF ULTRAGENYX PHARMACEUTICAL SECURITIES LITIGATION

Ultragenyx Pharmaceutical Inc. Securities Class Action Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law

Form 8-K

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Pomerantz LLP Calls Attention to Class Action Against Ultragenyx Pharmaceutical Inc. – RARE

RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!